See all

Updates: Lilly's Global COVID-19 Response

View Story

Increasing Diversity in Clinical Trials

View Story

Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial

View Story

Overcoming Barriers to Biomarker Testing in Cancer

View Story

Lilly’s Commitment to Quality Manufacturing

View Story

Still image from CAR-approved video; employee consent is on file

Lilly Global Day of Service Goes Virtual and Remote to Improve Health, Education and Communities

View Story

Press Releases

See all

New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

October 23, 2020

Tags |  Product

- Jardiance (empagliflozin) reduced risk for the composite endpoint of cardiovascular death and hospitalization for heart failure, as well as serious adverse kidney outcomes, in adults with or without chronic kidney disease at baseline. The trial included people with and without diabetes   -

Lilly Declares Fourth-Quarter 2020 Dividend

October 19, 2020

Tags |  Financial

INDIANAPOLIS , Oct. 19, 2020 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2020 of $0.74 per share on outstanding common stock. The dividend is payable December 10, 2020 , to shareholders of record at the close of

Lilly Announces Agreement to Acquire Disarm Therapeutics

October 15, 2020

Tags |  Corporate

Acquisition expands Lilly's R&D efforts in pain and neurodegeneration with the addition of Disarm's promising preclinical SARM1 programs for axonal degeneration INDIANAPOLIS and CAMBRIDGE, Mass. , Oct. 15, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced a definitive

Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial

October 12, 2020

Tags |  Product

‒ Results from the 52-week study showed continued symptom improvement and reduction of intestinal mucosal inflammation in patients with moderately to severely active Crohn's disease   ‒ These Phase 2 data reinforce the continued evaluation of mirikizumab in the ongoing, pivotal VIVID Phase 3